Paclitaxel-eluting balloon catheter - Cardionovum

Drug Profile

Paclitaxel-eluting balloon catheter - Cardionovum

Alternative Names: LegflowDCB; Paclitaxel-eluting coronary PTCA catheter - Cardionovum; PrimusDCB

Latest Information Update: 19 Oct 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cardionovum
  • Class Antineoplastics; Diterpenes; Paclitaxels; Small molecules; Taxanes
  • Mechanism of Action Immunosuppressants; Mitosis inhibitors; Proto-oncogene protein c-bcl-2 inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Coronary artery restenosis; Peripheral artery restenosis

Most Recent Events

  • 30 May 2013 Biomarkers information updated
  • 24 Sep 2012 Efficacy and adverse events data from a clinical trial and pharmacodynamic data from a preclinical trial in Coronary artery restenosis released by Cardionovum
  • 31 Mar 2012 Launched for Peripheral artery restenosis in Europe (Intra-arterial)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top